Key Highlights

  • Infinity Pharmaceuticals' proposed Merger with MEI Pharma was terminated in July 2023 after stockholders had already approved it, sending shares sharply lower.
  • The company subsequently announced a Value Preservation and Maximization Plan, language signaling a wind-down rather than a path back to growth.
  • Its lead asset, eganelisib, an oral PI3K-gamma inhibitor tested in combination with checkpoint inhibitors, never reached the market.
  • The Q-suffix ticker is consistent with a subsequent Bankruptcy process, and the last closing session showed essentially no movement at a sub-penny quote.

Infinity Pharmaceuticals, Inc (OTC:INFIQ) once carried real ambition in cancer immunotherapy, and for years its shares traded actively on Nasdaq under INFI. Today the story reads very differently. The ticker now appears as INFIQ, the letter markets attach to companies in bankruptcy, and the stock changes hands for a fraction of a cent in the last closing session.

Company and Latest Development

Infinity Pharmaceuticals was a clinical-stage company built around eganelisib (IPI-549), an oral, selective inhibitor of PI3K-gamma designed to reprogram the tumor microenvironment and boost the effect of checkpoint inhibitors. Its MARIO clinical program tested eganelisib in combinations for cancers including triple-negative breast cancer and head and neck cancer.

The defining event came in mid-2023: after stockholders had approved a proposed merger with MEI Pharma, the agreement was terminated in July 2023, sending the shares sharply lower. Infinity then announced a Value Preservation and Maximization Plan, language that signaled a wind-down rather than a path back to growth.

What Is Driving Attention Around INFIQ?

There is no verifiable, fresh corporate catalyst behind recent trading. The stock shows essentially no movement at a sub-penny quote, a profile typical of a former Nasdaq name that has been Delisted to the over-the-counter market and effectively gone dormant.

Any interest today is largely residual: index screens, ticker searches and speculative bottom-fishing in near-worthless shares. The meaningful developments for Infinity occurred in 2023, not in the current session.

Key Numbers and Company Position

Precise, current figures for a company in this state are not reliably verifiable, and a quote near one-millionth of a dollar and a nominal Market Value in the low tens of dollars should be treated as indicative rather than confirmed.

What is documented is the trajectory: a terminated MEI Pharma merger in July 2023, a value-preservation plan, and migration off Nasdaq. The company's lead asset, eganelisib, never reached the market.

What Could Come Next?

For a company in bankruptcy or dissolution, the next steps are procedural rather than commercial: court proceedings, potential sale or licensing of intellectual property tied to eganelisib, and eventual distribution of any remaining value under a priority waterfall that typically leaves common shareholders last.

Any filings in the bankruptcy docket or with the SEC would be the documents to monitor, but they are unlikely to restore Equity value.

Risks to Watch

The risks here are effectively terminal for common holders. Shares of bankrupt companies frequently end up canceled with no recovery, and sub-penny OTC trading brings extreme spreads, minimal Liquidity and a high probability of total loss.

There is no analyst coverage, no active pipeline generating value, and no confirmed near-term event capable of re-rating the stock.

A Failed Deal, Not a Pending One

Infinity Pharmaceuticals' arc, from a Nasdaq-listed immuno-oncology developer to a distressed, Q-suffixed micro-cap, is a cautionary study in how quickly a failed transaction and a stalled pipeline can erase a biotech's market standing.

There is no identifiable catalyst driving the shares today, only the residue of a 2023 wind-down. Investors tracking INFIQ may want to watch court and SEC filings for the disposition of the eganelisib assets, while recognizing that the equity itself carries little realistic prospect of recovery.